Novo Nordisk Chair Helge Lund & Six Directors Resign Amid Board Dispute

Novo Nordisk announced that Chair Helge Lund and six Independent Directors will step down following disagreements with the company’s top investor, the Novo Nordisk Foundation, over board composition and strategic priorities. The resignations are set to take effect after a shareholder meeting on November 14, 2025.

The Foundation cited differences regarding the pace of change and the focus on the U.S. market as key reasons behind the departures. The move follows ongoing discussions about Board renewal and governance, including support for Chief Executive Officer (CEO) Mike Doustdar’s restructuring initiatives.

Helge Lund is a member of the People and Governance Committee. He is Chair of BP plc, Inkerman AS, and Stiftelsen Værekraft and serves on the Boards of Belron SA and P/F Tjaldur. He is an operating advisor to Clayton Dubilier & Rice and a trustee of the International Crisis Group. Previously, he was CEO of BG Group plc, Equinor ASA, and Aker Kvaerner ASA. He holds an MBA from INSEAD and an MA in Economics from NHH, Norway, with expertise in global leadership, healthcare, finance, M&A, human capital, and ESG.

a

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: